The NeoTYPE Lung Tumor Profile analyzes 49 biomarkers through a combination of next-generation sequencing (NGS), other molecular methods, FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If global HER2 (Other) IHC w/Breast Scoring result is 2+, case will reflex to global HER2 (Other) FISH w/Breast Scoring unless reflex to tech-only FISH or reflex opt-out is requested. If Pan-TRK IHC is expressed or equivocal, reflex to either NTRK NGS Fusion Panel (Default) or NTRK 1-3 FISH Panel will be added. A microsatellite instability (MSI) NGS result of “indeterminate” will create a reflex to MSI by PCR as long as the tumor percentage is ≥40% and paired normal tissue is available.
- NGS (40 genes + 2 biomarkers): AKT1, ALK, ARID1A, ATM, ATR, ATRX, BRAF, CCND1, CDKN2A, CDKN2B, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KEAP1, KIT, KMT2D, KRAS (includes G12C mutation), MET, Microsatellite Instability (MSI), NF1, NFE2L2, NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, RB1, RBM10, RET, ROS1, SMARCA4, SMAD4, SMO, SRC, STK11, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
- Other Molecular (1 biomarker): MET Exon 14 Deletion Analysis
- FISH (5 biomarkers): ALK, MET, PTEN, RET, ROS1 (tech-only available)
- IHC (3 biomarkers): HER2 (Other) IHC w/Breast Scoring, PD-L1 22C3, Pan-TRK (tech-only available for HER2 and PD-L1)
The NeoTYPE Lung Tumor Profile characterizes primary or metastatic non-small cell tumors for the most significant genetic changes relevant to therapy decisions, prognosis, and clinical research. It is appropriate for patients with newly-diagnosed or recurrent disease, and for patients with resistant disease to explore options in clinical trials.
- FFPE tissue: Paraffin block preferred. Please use 10% buffered formalin fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
14 days